|
|
Volumn 45, Issue 3, 2007, Pages 188-
|
|
Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: A review of a special problem [2]
a
a
a
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIBIOTIC AGENT;
ANTIINFECTIVE AGENT;
CYTOCHROME P450 2C19;
LANSOPRAZOLE;
OMEPRAZOLE;
PROTON PUMP INHIBITOR;
RABEPRAZOLE;
ANTIBIOTIC RESISTANCE;
CLINICAL TRIAL;
DRUG METABOLISM;
DRUG TREATMENT FAILURE;
ERADICATION THERAPY;
GENETIC POLYMORPHISM;
GENETIC VARIABILITY;
GENOTYPE;
HELICOBACTER INFECTION;
HELICOBACTER PYLORI;
HUMAN;
LETTER;
META ANALYSIS;
OUTCOME ASSESSMENT;
PHARMACOGENETICS;
SYSTEMATIC REVIEW;
TREATMENT DURATION;
|
|
EID: 33947214021
PISSN: 09461965
EISSN: None
Source Type: Journal
DOI: 10.5414/cpp45188 Document Type: Letter |
|
Times cited : (3)
|
|
References (0)
|
